Size regimes similar to nab-paclitaxel (Abraxane), a 130-nm albumin-bound formulation of paclitaxel particles used routinely in the treatment of pancreatic cancer, should accumulate passively via the EPR effect (44, 45) and are likely to be more representative of human tumor vasculature than preclinical models, which may not translate as well to human scenarios. The gene discussed is ALB; the disease is familial pancreatic carcinoma.